ArticleNature communications2022
An in vivo gene amplification system for high level expression in Saccharomyces cerevisiae.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Enhancing delta-tocotrienol production inSynthetic and systems biotechnology · 2026Article
- rDNA-mediated multicopy integration and gene dosage quantification system for microbial zeaxanthin biosynthesis.World journal of microbiology & biotechnology · 2026Article
- Bioactivities and biosynthesis of monoterpene-based biopesticides: current state and perspectives.Microbial cell factories · 2026Review
- CRISPR-based synthetic biology toolkit development inSynthetic and systems biotechnology · 2026Article
- Push-pull-block framework for lycopene biosynthesis: a comprehensive review of metabolic engineering strategies inFrontiers in bioengineering and biotechnology · 2026Review
- Transposon engineering ofEngineering in life sciences · 2026Article
- Engineering the oleaginous yeast Yarrowia lipolytica for co-production of phenolic monoterpenes thymol and carvacrol.Microbial cell factories · 2025Article
- Production of borneol, camphor, and bornyl acetate using engineeredMetabolic engineering communications · 2025Article
- Article
- Cyanamide-inducible expression of homing nucleaseSynthetic and systems biotechnology · 2024Article
- High-level biosynthesis of enantiopure germacrene D in yeast.Applied microbiology and biotechnology · 2024Article
- Versatile filamentous fungal host highly-producing heterologous natural products developed by genome editing-mediated engineering of multiple metabolic pathways.Communications biology · 2024Article
- Facilitating stable gene integration expression and copy number amplification inSynthetic and systems biotechnology · 2024Article
- LowTempGAL: a highly responsive low temperature-inducible GAL system in Saccharomyces cerevisiae.Nucleic acids research · 2024Article
- Tandem gene duplication selected by activation of horizontally transferred gene in bacteria.Applied microbiology and biotechnology · 2024Article
- Profiling proteomic responses to hexokinase-II depletion in terpene-producingEngineering microbiology · 2023Article
- An outlook to sophisticated technologies and novel developments for metabolic regulation in theFrontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bottlenecks in metabolic pathways due to insufficient gene expression levels remain a significant problem for industrial bioproduction using microbial cell factories. Increasing gene dosage can overcome these bottlenecks, but current approaches suffer from numerous drawbacks. Here, we describe HapAmp, a method that uses haploinsufficiency as evolutionary force to drive in vivo gene amplification. HapAmp enables efficient, titratable, and stable integration of heterologous gene copies, delivering up to 47 copies onto the yeast genome. The method is exemplified in metabolic engineering to significantly improve production of the sesquiterpene nerolidol, the monoterpene limonene, and the tetraterpene lycopene. Limonene titre is improved by 20-fold in a single engineering step, delivering ∼1 g L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.